Literature DB >> 23162664

Changes in soluble fibrin levels during the perioperative period of gynecologic cancer surgery.

Junichi Kodama1, Noriko Seki, Chikako Fukushima, Tomoyuki Kusumoto, Keiichiro Nakamura, Atsushi Hongo, Yuji Hiramatsu.   

Abstract

The purpose of this study was to evaluate the changes in plasma soluble fibrin (SF) levels over time in gynecologic cancer patients following surgery. Furthermore, we examined the duration of the coagulation stage and determined a suitable duration for which thromboprophylaxis with anticoagulant agents should be administered. We retrospectively studied 311 patients with invasive gynecologic cancer who underwent surgery at Okayama University Hospital, Japan. The plasma SF levels were measured serially prior to the operation and on postoperative days 0, 1, 3, 5, 7, 10, 14, 21 and 28. The plasma SF levels increased rapidly, peaked on postoperative day 1 and then decreased. The SF levels of patients with venous thromboembolism (VTE) were significantly different from those of VTE-negative patients on postoperative days 0-10. The SF levels on each day did not significantly differ between patients treated with chemical anticoagulants and those treated mechanically. The plasma SF levels were elevated (≥7.0 μg/ml) in 159 of the 311 patients (51.1%) on one of the days when these levels were measured. Among the patients with elevated plasma SF levels, 110 patients (69.2%) peaked on days 0-3 and only 9 patients (5.7%) peaked on days 21-28. Although only 1 of the 14 patients (7.1%) who showed peak levels on day 14 had undergone chemotherapy following surgery, 8 of the 9 patients (88.9%) whose levels peaked on days 21-28 had undergone chemotherapy following surgery (P= 0.0002). In conclusion, the plasma SF levels increased rapidly, peaked on postoperative day 1 and then decreased. These levels peaked within 14 days of surgery in most cases. Therefore, chemical thromboprophylaxis may be administered for at least up to 14 days following surgery.

Entities:  

Year:  2012        PMID: 23162664      PMCID: PMC3499562          DOI: 10.3892/ol.2012.891

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  14 in total

1.  Incidence and timing of venous thromboembolism after surgery for gynecological cancer.

Authors:  Abraham Peedicayil; Amy Weaver; Xujian Li; Erin Carey; William Cliby; Andrea Mariani
Journal:  Gynecol Oncol       Date:  2010-12-22       Impact factor: 5.482

Review 2.  Extended perioperative thromboprophylaxis in patients with cancer. A systematic review.

Authors:  Elie A Akl; Irene Terrenato; Maddalena Barba; Francesca Sperati; Paola Muti; Holger J Schünemann
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

3.  Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.

Authors:  David Bergqvist; Giancarlo Agnelli; Alexander T Cohen; Amiram Eldor; Paul E Nilsson; Anne Le Moigne-Amrani; Flavia Dietrich-Neto
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

4.  Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoeitin.

Authors:  Amy Lin; Janice Ryu; Danielle Harvey; Barbara Sieracki; Sidney Scudder; Ted Wun
Journal:  Gynecol Oncol       Date:  2006-01-10       Impact factor: 5.482

5.  D-dimer level as a risk factor for postoperative venous thromboembolism in Japanese women with gynecologic cancer.

Authors:  J Kodama; N Seki; S Masahiro; T Kusumoto; K Nakamura; A Hongo; Y Hiramatsu
Journal:  Ann Oncol       Date:  2010-02-03       Impact factor: 32.976

Review 6.  Duration of venous thromboembolism prophylaxis after surgery.

Authors:  Clive Kearon
Journal:  Chest       Date:  2003-12       Impact factor: 9.410

7.  A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexed with fibrinogen or its derivatives: its application to the measurement of soluble fibrin in plasma.

Authors:  G Soe; I Kohno; K Inuzuka; Y Itoh; M Matsuda
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

8.  Changes of the soluble fibrin monomer complex level during the perioperative period of hip replacement surgery.

Authors:  Tomonori Misaki; Isao Kitajima; Tamon Kabata; Mineko Tani; Chiharu Kabata; Tsunehisa Tsubokawa; Hidesaku Asakura; Katsuro Tomita
Journal:  J Orthop Sci       Date:  2008-10-09       Impact factor: 1.601

9.  Elevated levels of soluble fibrin in patients with venous thromboembolism.

Authors:  Akihiro Tsuji; Hideo Wada; Takeshi Matsumoto; Yasunori Abe; Satoshi Ota; Norikazu Yamada; Takashi Sugiyama; Akihiro Sudo; Katsuya Onishi; Kaname Nakatani; Atsumasa Uchida; Masaaki Ito; Koji Suzuki; Tsutomu Nobori
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

Review 10.  Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review.

Authors:  M Heather Einstein; Elizabeth A Pritts; Ellen M Hartenbach
Journal:  Gynecol Oncol       Date:  2007-04-20       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.